Trials / Conditions / Non-Small-Cell Lung

Non-Small-Cell Lung

20 registered clinical trials studyying Non-Small-Cell Lung — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China NCT07316062	AstraZeneca	—
Not Yet Recruiting	Phase 1 Study of PF-08046033 in Advanced Solid Tumors NCT07519655	Pfizer	Phase 1
Not Yet Recruiting	Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanc NCT07489066	Pfizer	Phase 2
Recruiting	A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377	EpiBiologics	Phase 1
Recruiting	A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Active Not Recruiting	Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lu NCT05261399	AstraZeneca	Phase 3
Unknown	First-line Replacement Maintenance of Envafolimab in Advanced NSCLC NCT05465733	First Affiliated Hospital Xi'an Jiaotong University	Phase 2
Completed	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer NCT04362072	Pfizer	Phase 4
Unknown	A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carbo NCT03952403	Shanghai Henlius Biotech	Phase 3
Unknown	Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer NCT03766490	The First Affiliated Hospital of Soochow University	N/A
Terminated	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects NCT03626545	Novartis Pharmaceuticals	Phase 3
Unknown	Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC NCT03389256	Sichuan Cancer Hospital and Research Institute	Phase 2
Completed	A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resect NCT03456063	Hoffmann-La Roche	Phase 3
Completed	A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation NCT02834936	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
Completed	Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Thera NCT01041235	Azaya Therapeutics, Inc.	Phase 1
Completed	A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cel NCT00863746	Bayer	Phase 3
Completed	A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastati NCT00532155	Sanofi	Phase 3
Completed	Clinical Impact of EUS in Staging NSCLC NCT00577746	Indiana University	—
Completed	ZD6474(Vandetanib) + Alimta Combo Study NCT00506051	Genzyme, a Sanofi Company	Phase 1
Completed	Iressa Expanded Access Program (EAP) NCT00034879	AstraZeneca	Phase 3